2023 ASCO Annual Meeting

kidney cancer

Thomas E. Hutson, DO, PharmD, on RCC: Overall Survival Analysis of Lenvatinib, Pembrolizumab, and Sunitinib

Thomas E. Hutson, DO, PharmD, of Texas Oncology, discusses the 4-year follow-up results from the CLEAR study for patients with advanced renal cell carcinoma (RCC). The data showed that lenvatinib plus...


Claire Roddie, PhD, MBChB, on B-ALL: Safety and Efficacy Data of Obecabtagene Autoleucel

Claire Roddie, PhD, MBChB, of University College London, discusses results of the FELIX study, which showed that the second-generation chimeric antigen receptor (CAR) T-cell therapy obecabtagene autol...


Eunice S. Wang, MD, and Gregory Roloff, MD, on B-ALL: Outcomes With Brexucabtagene Autoleucel in Adult Patients

Eunice S. Wang, MD, of Roswell Park Comprehensive Cancer Center, and Gregory Roloff, MD, of the University of Chicago, discuss data that are the first to demonstrate post–FDA approval efficacy and tox...

Lung Cancer

Patients With SLFN11-Expressing SCLC May Benefit From Immune Checkpoint Inhibitor Plus PARP Inhibitor

Among patients with extensive-stage small cell lung cancer (SCLC) positive for expression of the Schlafen-11 gene (SLFN11), those who received maintenance treatment with the immune checkpoint inhibito...

Issues in Oncology

Changes in RECIST Tumor Measures Correlate Linearly With Survival in Patients Treated With Checkpoint Inhibitors

The Response Evaluation Criteria in Solid Tumors (RECIST), used in many clinical trials to evaluate changes in tumor burden over time, classify objective tumor response into one of four categories—com...


Muhit Özcan, MD, on DLBCL: Now Recruiting Previously Untreated Patients for a Study of Zilovertamab Vedotin Plus Chemotherapy

Muhit Özcan, MD, of Turkey’s Ankara University School of Medicine, discusses waveLINE-007, a two-part study now recruiting in more than 20 locations, to determine the safety and recommended phase II d...


Muhit Özcan, MD, on DLBCL: Early Results on Zilovertamab Vedotin

Muhit Özcan, MD, of Turkey’s Ankara University School of Medicine, discusses phase II findings from the waveLINE-004 study. It showed that the antibody-drug conjugate zilovertamab vedotin had clinical...

colorectal cancer

Sebastian Stintzing, MD, on Colorectal Cancer: Influence of Liquid Biopsy in First-Line Combination Treatment

Sebastian Stintzing, MD, of the Charité Universitätsmedizin Berlin, discusses results from the phase III FIRE-4 study, which showed that liquid biopsy is clinically relevant in verifying mutational st...


LaQuisa C. Hill, MD, on Relapsed or Refractory T-ALL: New Data on CD5 CAR T Cells

LaQuisa C. Hill, MD, of Baylor College of Medicine, Houston Methodist Hospital, discusses study findings showing that CD5 chimeric antigen receptor (CAR) T cells may induce clinical responses in heavi...

CNS Cancers

Is Pembrolizumab Effective in Patients With Brain Metastases?

In a phase II clinical trial, investigators found that 42% of patients with brain metastases benefited from treatment with the immune checkpoint inhibitor pembrolizumab, with 7 of the 57 patients in t...

Hematologic Malignancies

Veterans Exposed to Agent Orange May Be at Increased Risk of Developing Myeloproliferative Neoplasms

A population-based study using information from a database of veterans found that those who had been exposed to Agent Orange may be at an increased risk of developing myeloproliferative neoplasms (MPN...

Issues in Oncology
Pain Management

Impact of Changing Opioid Prescription Landscape for Patients With Cancer

Despite the common use of opioids in clinical settings, new and persistent opioid prescriptions have declined among patients both with and without cancer, according to new findings presented by Baum e...

Bladder Cancer

Early Cessation of Neoadjuvant Chemotherapy May Lead to Worse Outcomes in Patients With Muscle-Invasive Bladder Cancer

Patients with muscle-invasive bladder cancer who receive fewer than three cycles of chemotherapy prior to cystectomy may have an increased risk of cancer recurrence and worse survival outcomes, accord...

Hepatobiliary Cancer

Zanidatamab Shows Activity in Refractory HER2-Amplified Biliary Tract Cancer

The HER2-targeted bispecific antibody zanidatamab demonstrated durable responses in patients with treatment-refractory HER2-positive biliary tract cancer, according to research presented by Shubham Pa...

Gynecologic Cancers

Addition of Olaparib and Durvalumab to Standard of Care May Prolong Progression-Free Survival in Patients With Advanced Ovarian Cancer

Patients with newly diagnosed advanced ovarian cancer without a BRCA mutation who received durvalumab and olaparib in addition to the standard of care had improved progression-free survival compared w...

Breast Cancer

Adding Ribociclib to Endocrine Therapy May Reduce Recurrence Risk in Patients With Hormone Receptor–Positive, HER2-Negative Early-Stage Breast Cancer

Adding the CDK4/6 inhibitor ribociclib to endocrine therapy resulted in a significant improvement in invasive disease–free survival for patients with hormone receptor–positive, HER2-negative early-sta...

Gynecologic Cancers

Simple Hysterectomy May Be a Safe Option for Patients With Early-Stage, Low-Risk Cervical Cancer

Simple hysterectomy with pelvic lymph node dissection may be a safe treatment option for patients with early-stage, low-risk cervical cancer and may help improve quality of life, according to results ...

gynecologic cancers

Marie Plante, MD, on Cervical Cancer: New Data on Hysterectomy and Pelvic Node Dissection

Marie Plante, MD, of Canada’s Université Laval and the CHUQ Hotel Dieu de Québec, discusses phase III results from a study that compared radical hysterectomy and pelvic node dissection vs simple hyste...

Bladder Cancer

Extended Lymphadenectomy May Not Benefit Patients With Clinically Localized Muscle-Invasive Bladder Cancer

Extended lymphadenectomy in patients undergoing radical cystectomy for clinically localized muscle-invasive bladder cancer was not associated with improved disease-free survival or overall survival an...

Colorectal Cancer

Study Finds Wide Variations in Intratumoral Microbiome of Patients With Early- vs Late-Onset Colorectal Cancer

Researchers have found that the bacteria, fungi, and viruses within the tumors of patients with colorectal cancer varied significantly depending on whether they were diagnosed with early-onset or late...

Global Cancer Care

ATOM Coalition Seeks to Ensure Equitable Cancer Care in Low- and Middle-Income Countries

A new global health initiative, the Access to Oncology Medicines (ATOM) Coalition, may be capable of reducing the burden of suffering and death from cancer in low- and middle-income countries by impro...

Pancreatic Cancer

Minimally Invasive Distal Pancreatectomy in Patients With Resectable Pancreatic Cancer

Results from the international, randomized DIPLOMA trial ( identifier NCT04483726) comparing minimally invasive distal pancreatectomy (MIDP) with open distal pancreatectomy (ODP) in ...

Global Cancer Care

Using a Health Systems Strengthening Approach in the United States–Mexico Border Region Improved Survival Rates for Children With ALL

The implementation of a collaborative program between North American and Mexican medical institutions to achieve sustainable, high-quality care at a public hospital in the United States–Mexico border ...

Breast Cancer

Telephone-Based Weight Loss Intervention for Patients With Breast Cancer and Overweight/Obesity

A randomized study by Jennifer A. Ligibel, MD, Director of the Leonard P. Zakim Center for Integrative Therapies and Healthy Living at Dana-Farber Cancer Institute, and Associate Professor of Medicine...

Gastrointestinal Cancer
Health-Care Policy

Medicaid Expansion Associated With a Reduction in Mortality for Black Patients With Gastrointestinal Cancers

Studies showed that racial minorities experience disparities in access to cancer treatment and survival. In an effort to improve access to care for disadvantaged populations, the Affordable Care Act p...

Myelodysplastic Syndromes

Luspatercept Improves Reliance on Blood Transfusions for Patients With Lower-Risk MDS

Patients with lower-risk myelodysplastic syndromes (MDS) who received luspatercept to treat anemia instead of erythropoiesis-stimulating agents (ESAs)—the current standard of care—needed fewer blood t...

Gynecologic Cancers

Adding Pembrolizumab to Chemotherapy May Improve Survival in Patients With Advanced Cervical Cancer

Adding the PD-1 inhibitor pembrolizumab to chemotherapy, with or without bevacizumab, improved overall survival and progression-free survival in patients with persistent, recurrent, or metastatic cerv...